JNCE Jounce Therapeutics, Inc.

22.28
+1  (3%)
Previous Close 21.53
Open 21.59
Price To book 0.00
Market Cap 54.01M
Shares 2,424,000
Volume 242,216
Short Ratio 1.85
Av. Daily Volume 226,185

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiated September 2017.Safety data due at ASCO June 3, 2017. Abstract 11602. Phase 2 arm initiation announced April 21, 2017.
JTX-2011
Solid tumors - Cancer

Latest News

  1. Merck KGaA says dominance in liquid crystals could be at risk
  2. Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors
  3. Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : April 14, 2017
  4. Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
  5. Jounce Therapeutics to Present at AACR Annual Meeting on JTX-2011 Cancer Immunotherapy Program
  6. Jounce Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
  7. New ​Cambridge-based, Third Rock-backed biotech revealed in federal filing
  8. Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
  9. Lexington's Agenus quietly discloses failure of cancer vaccine trial
  10. ​Lexington-based Agenus reworks Incyte pact, freeing up $80M in cash
  11. Robust Start for Pharmaceutical IPOs In 2017
  12. ($$) Braeburn Pharmaceuticals Puts IPO Plans On Hold
  13. Celgene Subsidiary Invests in Jounce Therapeutics
  14. ($$) Shares in Two Biotechs Rise Post-IPO
  15. IPO Market Looking for 7 Offerings This Week
  16. Jounce Adds Juice To IPO Market After Unicorn AppDynamics Acquired
  17. After $97M IPO, Swiss biotech to open U.S. headquarters in Boston
  18. Jounce Therapeutics Upsizes IPO to $16 a Share